NAMPT and non-small cell lung carcinoma: Depletion or inhibition of NAMPT has been shown to increase ROS in models of NSCLC (40), leukemia (43, 97), prostate cancer (19), breast cancer (61), glioblastoma (102), CRC (112), and others (85).